Abzena invests $60m into cGMP manufacturing capacity
The facility will enable the company to deliver Phase I to commercial manufacturing services for biologic projects.
Abzena, a contract provider of integrated discovery, development and manufacturing services for biologics and bioconjugates, has invested $60 million into a new facility for late-phase and commercial cGMP manufacturing.
The new 50,000 sq. ft ‘Lusk’ facility, at the company’s site in San Diego, CA, USA, houses a process development laboratory and two new cGMP manufacturing cleanrooms for 500 L and 2,000 L scale in Sartorius single-use bioreactors. The facility also houses a GMP warehouse, and analytical development and quality control laboratories.
The new 7,400 sq. ft process development laboratory uses Sartorius single-use technology (SUT) bioreactors from Ambr 250 mL to 2 L, 50 L and 200 L STR bioreactor to screen important process parameters to develop robust scaleable processes and ensure seamless manufacturability.
Until now, the company's other San Diego site has been focused primarily on developing and manufacturing Phase I and II clinical trial materials.
This investment has been driven by both existing customer requirements and by wider market demand. The facility will enable the company to deliver Phase I to commercial manufacturing services for biologic projects.
"This expansion will allow us to provide seamless project integration for our customers as they move into Phase III and ultimately commercial manufacture, " said Matt LeClair, Senior Vice President (SVP) and Site Head of Abzena’s San Diego Operations.
To date the San Diego facility has completed hundreds of projects and has had more than 40 successful audits carried out by key customers. The new facility has also received its manufacturing license from the California Food and Drug Branch (FDB).
The addition of the new facility has also created 125 new positions within the company.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance